Abstract:Objective To assess the association of BDNF gene Val66Met polymorphism with efficacy of antidepressant treatment and plasma BDNF level.Methods Two hundred and forty-nine ethnic Han Chinese patients with depression(study group),who have met the diagnostic criteria of DSM-Ⅳ,were prescribed with venlafaxine or paroxetine.Two hundred and two healthy individuals were recruited as the control group.General demographic information such as gender,age,educational status,occupation,and marriage status were collected.HAMD-17 was adopted as the primary rating tool to evaluate the severity of depression on the baseline and at the end of 1st,2nd,4th,6th week of treatment.PCR-restriction fragment length polymorphism was applied to determine the Val66Met polymorphism of the BDNF gene in the two groups.Plasma BDNF concentration was measured with ELISA before and after 6 weeks of treatment.Results No significant differences have been found in HAMD scores and reduction of HAMD scores on the baseline and at the end of 1 st,2nd,4th,6th weeks of treatment for each genotype.Nor were significant differences found in the Val66Met genotypes and allelic frequency between patients who achieved remission or not after 6 weeks' treatment as well as the healthy volunteers.The plasma BDNF level in depression patients was lower than that in healthy controls.The BDNF level has increased significantly after 6 weeks' treatment with both venlafaxine and paroxetine,but was still lower than the healthy controls.The BDNF level in the patients achieved remission who were treated with venlafaxine was similar to the normal controls,while those treated with paroxetine was still lower than normal controls.The BDNF level in patients who have not achieved remission was lower than normal controls.The BDNF level was not associated with the Val66Met polymorphism on the baseline and the end of 6th week.Conclusion No association has been found between the efficacy of venlafaxine or paroxetine and the BDNF Val66Met polymorphism.The BDNF level of patients with depression is significantly lower than healthy controls on the baseline,and can be enhanced with the treatment.Particularly,the BDNF level in patients who achieved remission after the treatment of venlafaxine can rise to normal.The level of BDNF has certain value in the forecasting of efficacy in the anti-depression therapy.BDNF level is not associated with the Val66Met polymorphism of the BDNF gene.

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.

Association Of Brain-Derived Neurotrophic Factor Genetic Val66met Polymorphism With Severity Of Depression, Efficacy Of Fluoxetine And Its Side Effects In Chinese Major Depressive Patients

Effect of brain-derived neurotrophic factor Val66Met polymorphism and environmental factors on antidepressant treatment

Research on association of BDNF gene Val66Met polymorphism with efficacy of antidepressants and plasma BDNF level

Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder.

Association of BDNF gene polymorphism with major depression and cognitive functions

Brain-derived Neurotrophic Factor’s Val66Met and C270T Polymorphisms Influence Citalopram/Escitalopram Response in Chinese Patients with Major Depressive Disorder

Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population.

Functional Val66Met polymorphism of Brain-derived neurotrophic factor in type 2 diabetes with depression in Han Chinese subjects

Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population.

BDNF Val66Met Polymorphism and Anxiety/depression Symptoms in Schizophrenia in a Chinese Han Population.

Plasma Brain-Derived Neurotrophic Factor (BDNF) Concentration and the BDNF Val66Met Polymorphism in Suicide: a Prospective Study in Patients with Depressive Disorder

The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis.

Interaction Between Job Stress and the BDNF Val66Met Polymorphism Affects Depressive Symptoms in Chinese Healthcare Workers.

BDNF Val66Met Polymorphism, Life Stress and Depression: A Meta-Analysis of Gene-Environment Interaction

Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants

Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis

Meta-analysis of the association of brain-derived neurotrophic factor Val66Met polymorphism with obsessive-compulsive disorder.

Positive Association Between the Brain-Derived Neurotrophic Factor (bdnf) Gene and Bipolar Disorder in the Han Chinese Population

Association of Val66Met polymorphism of brain-derived neurotrophic factor gene with cognitive impairment and clinical symptoms in first-episode schizophrenia

Impact Of Brain-Derived Neurotrophic Factor Val66met Polymorphism On Cortical Thickness And Voxel-Based Morphometry In Healthy Chinese Young Adults